The earnings call highlighted strong growth across several segments, particularly in medical devices and adult nutrition, alongside effective financial management and strategic guidance for 2025. However, challenges such as foreign exchange impacts, market dynamics in China, and an increased tax rate were noted.

Company Guidance

During Abbott's Fourth Quarter 2024 Earnings Conference Call, the guidance for 2025 included expectations for robust growth across various metrics. Abbott forecasted organic sales growth to range between 7.5% and 8.5%, aiming for adjusted earnings per share (EPS) between $5.05 and $5.25, reflecting double-digit growth at the midpoint. The company outlined significant achievements in 2024, such as a 9.5% sales growth excluding COVID testing, a 70 basis point improvement in gross margins, and generating $8.5 billion in operating cash flow. For 2025, Abbott anticipates further expansion in its gross margin profile to around 57% of sales and an improvement in its adjusted operating margin profile by 150 basis points, driven by a combination of gross margin expansion and operating margin leverage. The adjusted tax rate is expected to increase to a range of 16% to 17% due to the adoption of the Pillar 2 tax framework. Abbott also highlighted strong performance across its business segments, including Nutrition, Diagnostics, and Medical Devices, and emphasized its commitment to innovation and operational excellence to sustain growth momentum.

Strong Sales Growth

Achieved sales growth of 9.5% excluding COVID testing, with significant contributions from adult nutrition and medical devices. Fourth quarter sales grew 10%, excluding COVID testing sales.

Record Operating Cash Flow

Generated $8.5 billion of operating cash flow, which supported reinvestment in the business, debt repayment, and $5 billion returned to shareholders.

Medical Devices Performance

Medical Devices sales grew 14%, with notable growth in Diabetes Care (23%), Structural Heart (23%), and Electrophysiology (9%).

2025 Guidance

Forecasted organic sales growth of 7.5% to 8.5% for 2025, with adjusted earnings per share expected to be in the range of $5.05 to $5.25, indicating double-digit growth at the midpoint.

---

Abbott Laboratories (GB:0Q15) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GB:0Q15 Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jul 18, 2018	2018 (Q2)	- / 0.73	0.62	17.74% (+0.11)	―	―
Oct 17, 2018	2018 (Q3)	- / 0.75	0.66	13.64% (+0.09)	―	―
Jan 23, 2019	2018 (Q4)	- / 0.81	0.74	9.46% (+0.07)	―	―
Apr 17, 2019	2019 (Q1)	- / 0.63	0.59	6.78% (+0.04)	―	―
Jul 17, 2019	2019 (Q2)	- / 0.82	0.73	12.33% (+0.09)	―	―
Oct 16, 2019	2019 (Q3)	- / 0.84	0.75	12.00% (+0.09)	―	―
Jan 22, 2020	2019 (Q4)	- / 0.95	0.81	17.28% (+0.14)	―	―
Apr 16, 2020	2020 (Q1)	- / 0.65	0.63	3.17% (+0.02)	―	―
Jul 16, 2020	2020 (Q2)	- / 0.57	0.82	-30.49% (-0.25)	―	―
Oct 21, 2020	2020 (Q3)	- / 0.98	0.84	16.67% (+0.14)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

GB:0Q15 Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jan 22, 2025	$116.02	$117.65	+1.40%
Oct 16, 2024	$115.66	$117.59	+1.67%
Jul 18, 2024	$104.09	$99.20	-4.69%
Apr 17, 2024	$108.42	$104.38	-3.73%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---